ZA868886B - Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications - Google Patents

Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications

Info

Publication number
ZA868886B
ZA868886B ZA868886A ZA868886A ZA868886B ZA 868886 B ZA868886 B ZA 868886B ZA 868886 A ZA868886 A ZA 868886A ZA 868886 A ZA868886 A ZA 868886A ZA 868886 B ZA868886 B ZA 868886B
Authority
ZA
South Africa
Prior art keywords
perturbations
prophylactic
carbohydrate
viruses
diagnostic
Prior art date
Application number
ZA868886A
Other languages
English (en)
Inventor
Gerard A Quash
John Dennis Rodwell
Thomas Joseph Mckearn
Jean Pierre Ripoll
Original Assignee
Gerard A Quash
John Dennis Rodwell
Thomas Joseph Mckearn
Jean Pierre Ripoll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerard A Quash, John Dennis Rodwell, Thomas Joseph Mckearn, Jean Pierre Ripoll filed Critical Gerard A Quash
Publication of ZA868886B publication Critical patent/ZA868886B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/812—Infectious mononucleosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA868886A 1985-11-25 1986-11-24 Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications ZA868886B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8517377A FR2590674B1 (fr) 1985-11-25 1985-11-25 Nouveaux reactifs de diagnostic

Publications (1)

Publication Number Publication Date
ZA868886B true ZA868886B (en) 1987-08-26

Family

ID=9325114

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA868886A ZA868886B (en) 1985-11-25 1986-11-24 Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications

Country Status (7)

Country Link
US (2) US4853326A (xx)
EP (1) EP0230166A1 (xx)
JP (2) JPS63501980A (xx)
AU (1) AU4283389A (xx)
FR (1) FR2590674B1 (xx)
WO (1) WO1987003372A1 (xx)
ZA (1) ZA868886B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340927C (en) * 1987-10-09 2000-03-14 Peter S. Linsley Method for increasing the sensitivity of assays for target ligand
US5252556A (en) * 1990-03-30 1993-10-12 New England Medical Center Hospitals, Inc. Fragment capable of binding anti-CD43 autoantibodies
EP0530216A4 (en) * 1990-04-19 1993-06-30 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
AU644210B2 (en) * 1990-07-19 1993-12-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5856106A (en) * 1995-11-01 1999-01-05 Biotransplant, Inc. Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
RU2218179C2 (ru) 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
WO1998013046A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
HUP0103382A3 (en) 1998-07-06 2002-12-28 Guilford Pharmaceuticals Inc B Naaladase inhibitors useful as pharmaceutical compounds and compositions
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
EP1135684B1 (en) * 1998-12-01 2006-01-11 Viral Antigens, Inc. IMPROVED SPECIFICITY IN THE DETECTION OF ANTI-RUBELLA IgM ANTIBODIES
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
DK1265928T3 (da) * 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
DK1259547T3 (da) * 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20080050391A1 (en) * 2004-03-30 2008-02-28 Lazarus Alan H Method for Treating Autoimmune Diseases With Antibodies
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
WO2008039171A2 (en) * 2005-08-08 2008-04-03 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5697677B2 (ja) 2009-10-26 2015-04-08 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
WO2011093858A1 (en) * 2010-01-27 2011-08-04 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
FR2966248B1 (fr) 2010-10-18 2020-05-01 Centre National De La Recherche Scientifique (Cnrs) Procede de fonctionnalisation de surfaces pour la detection d'analytes
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
DK2676137T3 (en) * 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2729807B1 (en) 2011-07-06 2016-08-17 Nestec S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20140051184A1 (en) * 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
ES2735085T3 (es) 2014-12-05 2019-12-16 Nestle Sa Ensayos de cambio de movilidad homogéneos indirectos para la detección de agentes biológicos en muestras de pacientes
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP6889990B2 (ja) * 2016-07-29 2021-06-18 株式会社カネカ 検査具

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA663229A (en) * 1963-05-14 Columbian Carbon Company Treatment of microorganisms
US3326767A (en) * 1966-03-21 1967-06-20 Abbott Lab Avian leukosis treatment with inactivated rous sarcoma virus
US3839555A (en) * 1971-03-26 1974-10-01 Rit Rech Ind Therapeut Vaccine adjuvant and method
CA1083508A (fr) * 1975-11-13 1980-08-12 Jacques Grange Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique
FR2331567A1 (fr) * 1975-11-13 1977-06-10 Inst Nat Sante Rech Med Nouveau procede de fixation chimique sur un support, de composes organiques comportant un residu glucidique et produits obtenus par ce procede
FR2378094A2 (fr) * 1977-01-24 1978-08-18 Inst Nat Sante Rech Med Nouveaux reactifs biologiques constitues par des supports solides sur lesquels sont couples des composes organiques comportant un residu glucidique
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
CA1101101A (en) * 1977-07-11 1981-05-12 Enn Vali Variable response notch filter for machine resonance elimination in a servo control system
DE2733380A1 (de) * 1977-07-23 1979-02-08 Behringwerke Ag Immunologisches analysenverfahren
JPS54113492A (en) * 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
FR2450877A1 (fr) * 1979-03-06 1980-10-03 Inst Nat Sante Rech Med Nouveaux tests par agglutination pour la detection des virus de la grippe, et reactifs pour la realisation de ces tests
FR2502786B1 (fr) * 1981-03-24 1985-06-21 Stallergenes Laboratoire Procede de fixation d'antigenes et d'anticorps sur support de polysaccharides, et utilisation du produit ainsi obtenu pour les dosages immunologiques
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4459360A (en) * 1981-10-05 1984-07-10 Mast Medical Industries, Ltd. Multiple-component binding assay system and method of making and using it
US4604348A (en) * 1981-11-19 1986-08-05 New York Blood Center, Inc. Composition for use in immunoassays
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
EP0117657A1 (en) * 1983-02-01 1984-09-05 Genentech, Inc. Rabies immunogenic polypeptides and vaccine using them, DNA sequences, expression vectors, recombinant cells, and cultures therefor, and processes for their production
FR2543570B1 (fr) * 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
EP0151579B1 (en) * 1983-04-27 1995-09-06 The President And Fellows Of Harvard College Method and products for detection of human t cell leukemia virus
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
CA1223222A (en) * 1984-02-22 1987-06-23 Nanibhushan Dattagupta Immobilized nucleic acid-containing probes
DE3416933A1 (de) * 1984-05-04 1985-11-07 Dora 1000 Berlin Köhler Mit antigenen oder antikoerpern beschichteter traeger
IL71947A (en) * 1984-05-29 1987-10-30 Yeda Research And Dev Comp Ltd Enzyme hydrazides and method for detection and determination of glycoconjugates
EP0203177A4 (en) * 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES AGAINST DEGGLYCOSILIZED VIRAL GLYCOPROTEINS.

Also Published As

Publication number Publication date
JPS63501980A (ja) 1988-08-04
EP0230166A1 (fr) 1987-07-29
US4853326A (en) 1989-08-01
FR2590674B1 (fr) 1989-03-03
JPS63502927A (ja) 1988-10-27
FR2590674A1 (fr) 1987-05-29
US4965069A (en) 1990-10-23
WO1987003372A1 (fr) 1987-06-04
AU4283389A (en) 1990-04-05

Similar Documents

Publication Publication Date Title
ZA868886B (en) Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications
ZA853026B (en) Leukemia-associated virus immunogen,vaccine and assay
EP0201165A3 (en) Medicaments for the treatment of emesis, anxiety and irritable bowel syndrome
IL68749A (en) Modified antigens,their preparation and vaccines containing them
ZA862812B (en) Antigens related to envelope glycoprotein of the virus of aids,methods of obtaining these antigens and means employed in these methods
ZA864879B (en) Vaccines and diagnostics derived from boving diarrhoea virus
IL79954A0 (en) Attenuated pseudorabies virus and vaccine containing same
CS382491A3 (en) N-oxides of alpha, alpha-diaryl-4-aryl-4-hydroxy-1-piepridinebutaneamides, process of their preparation and pharmaceuticals based thereon
EP0249611A4 (en) T-LYMPHOTROPHIC VIRUS.
EP0200051A3 (en) Process for the preparation of imidates, and phenyl-substituted imidates
AU6170486A (en) Defective viral vaccines
GB8620371D0 (en) Viral isolates
EP0225433A3 (en) Hydroxyoxaalkyl melamines, process for their preparation and their use
GB8500918D0 (en) Viral isolates
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
ZA866649B (en) Combination preparations for the treatment of malaria
EP0236487A4 (en) INACTIVATION OF A VIRUS.
GR3034271T3 (en) Pseudorabies virus protein.
IL82563A0 (en) Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic,prophylactic and/or therapeutic applications
NZ226569A (en) Process for the two-stage inactivation of viruses using both heat and alkalisation
HUT44439A (en) Process for inhibiting the reproduction of viruses and virus infections
ZW24886A1 (en) New ortho-anisamides,process for their preparation and their therapeutic applications
EP0259617A3 (en) Process and preparation for inactivating viruses
ZA876168B (en) Human low fc epsilon-receptor,the isolation,the recombinant preparation and purification thereof
GB2185908B (en) Process for the preparation of catalyst supports and materials produced thereby